What a Wegovy Compounding Pharmacy Actually Sells in 2026

Is "compounded Wegovy" actually a real, legal thing?

No, and it's worth clearing that up before anything else. Wegovy is Novo Nordisk's trademarked, FDA-approved brand of semaglutide, approved specifically for chronic weight management at a higher maximum dose than its sibling drug Ozempic. A trademark protects the finished product as a whole — the name, Novo Nordisk's manufacturing process, and the FDA's review of that exact formulation. No compounding pharmacy has a legal path to copy that finished product and sell it under Novo Nordisk's name. What a licensed pharmacy can do is compound the active molecule, semaglutide, under its own generic name, for a specific patient with a documented clinical reason the commercial product doesn't meet. When a telehealth ad says "compounded Wegovy," it's either sloppy shorthand for compounded semaglutide, or it's misrepresenting what it actually sells — and for a purchase this size, that difference is worth pausing on.

Novo Nordisk has been unusually aggressive about defending that line, and Wegovy specifically has been a repeated target. The company has filed well over 100 lawsuits against compounding pharmacies, med spas, and telehealth sellers across dozens of states, and in April 2025 won a permanent injunction against one compounding pharmacy that had marketed knockoff drugs as Wegovy or Ozempic — the court also ordered corrective disclosures telling patients the products were never FDA-reviewed. None of that means compounded semaglutide itself is fake or illegal. It means selling it under the Wegovy name specifically is the part Novo Nordisk keeps winning in court, and a provider that does it anyway is telling you something about how it operates.

• Wegovy = Novo Nordisk's trademarked, FDA-approved semaglutide brand for chronic weight management — cannot legally be compounded or sold under that name by anyone else.
• Compounded semaglutide = the same active molecule, mixed by a licensed 503A pharmacy for an individual patient — legally a distinct, non-branded product.
• A provider marketing "compounded Wegovy" as an actual product name, rather than clearly saying "compounded semaglutide," is misusing a trademark — and it's itself a red flag worth taking seriously.

Is compounding semaglutide — the Wegovy alternative — still legal in 2026?

Yes, but through a narrower door than during the 2022–2024 shortage years. Semaglutide sat on the FDA's drug shortage list, which let compounding pharmacies produce it broadly for anyone who wanted it. The FDA declared that shortage resolved on February 21, 2025, and after a court declined to block the change, enforcement discretion for 503A pharmacies ended April 22, 2025, with 503B outsourcing facilities following on May 22, 2025.

What survived is the 503A individual-patient pathway. A state-licensed compounding pharmacy can still legally prepare semaglutide for a specific, named patient when a prescriber documents a genuine clinical reason the commercial drug won't work — a documented allergy to an inactive ingredient, for instance. Wanting a lower price than Wegovy isn't, on its own, a qualifying reason under current FDA guidance, even though cost is the reason most women end up here. On April 30, 2026, the FDA separately proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list entirely. The public comment window has since been reported both as closing June 29, 2026 and as extended into late July 2026 — sources disagree, and no final rule had been issued as of this writing. Either way, that proposal targets 503B bulk compounding, which had already wound down; it doesn't touch the 503A pathway every provider below uses.

How much less does compounded semaglutide cost than brand-name Wegovy?

This is the actual money question, and the gap is real. Wegovy's list price at a retail pharmacy with no program runs about $1,349 a month — close to $16,200 a year, a figure almost nobody who's shopping around actually pays. Novo Nordisk's own NovoCare self-pay program brings that down considerably for the uninsured: the newer Wegovy tablet starts at $149 a month at the lowest doses, stepping up to $199 and eventually $299 a month at the higher strengths, while the injectable pen runs $199 a month for the first two fills before settling at $349 a month, or $399 at the highest dose. Commercially insured women whose plan covers Wegovy can use the manufacturer's savings card to get to $25 a month — the cheapest path of all, and nothing on this page beats it if you qualify. For the full pathway-by-pathway breakdown, see Wegovy cost.

Compounded semaglutide, by contrast, runs about $150 to $300 a month all-in across the reputable providers below — cash-pay only, with no insurance billing possible on either side.

• Full retail Wegovy, no program at all ($1,349/mo): about $16,188 a year.
• NovoCare self-pay pen at maintenance ($349/mo): about $4,188 a year.
• Compounded semaglutide at the lower end of this list ($149–$178/mo): roughly $1,788 to $2,136 a year — about $14,000 less than full retail, and around $2,000 to $2,400 less than NovoCare's own self-pay pen once past its intro period.
• Commercially insured women on the Wegovy savings card (~$25/mo): the cheapest path of all, at about $300 a year — compounded semaglutide won't beat this if you qualify.

Where to find a reliable Wegovy-alternative compounding pharmacy

The table above covers the five programs we could verify still compound semaglutide under the 503A model, with dated, all-in prices rather than a teaser number. One name worth addressing directly: Ro, once a major compounded-semaglutide seller, has exited that business. As of mid-2026, Ro sells only FDA-approved brand-name product — Wegovy pill from roughly $149 a month, Wegovy pen from roughly $199 a month intro, on top of a Ro Body membership around $145 a month — no compounded option at all. If a site still advertises Ro as a cheap compounded source, that listing is stale.

Curex — lowest starting price, no membership fee

Curex publishes a flat "from $149" for compounded semaglutide with no separate membership fee layered on top — a rarer structure than it should be in this category. The consult, the medication, and shipping are folded into that single number, with unlimited follow-ups and dose adjustments included. The caveat is the word "from": Curex doesn't publish a full maintenance-dose price ladder, so the starter-dose rate you see advertised may not be what you're paying once you've titrated up. Ask for the complete schedule in writing before enrolling.

Mochi Health — flat medication fee plus a separate membership

Mochi splits its billing into two lines: a flat $99-a-month medication fee that never rises with dose, plus a separate $79-a-month membership covering its ABOM-certified physician network. Add them together and the real all-in cost is about $178 a month — worth knowing before you're quoted the smaller number on the homepage. The medication price staying flat as you go up in dose is a genuine advantage over programs that quietly charge more at higher strengths.

Fridays — coaching and dietitian access bundled in

Fridays prices itself as a program rather than just a prescription: about $150 a month on a 12-month prepay, or $249 a month month-to-month, with dietitian access and group coaching included at either tier. The trade-off is the commitment behind the lower number — Fridays' BBB profile shows a recurring pattern of complaints about refund difficulty on prepaid plans, worth weighing before you commit a full year upfront.

Henry Meds — fully bundled, oral or injectable

Henry Meds bundles the medication, clinician visits, supplies, and shipping into one number that doesn't move as your dose does — oral from $249 a month, injection from $297 a month, no separate membership fee. That flat structure has been the most consistently verified figure we've seen in this category across repeated checks. Plans run month-to-month with no minimum term, though labs aren't included and you'll need to arrange bloodwork separately. See our Henry Meds review for the full picture.

Willow — flat pricing with LegitScript certification

Willow charges a single flat rate for compounded semaglutide — $299 a month regardless of dose, no membership fee, with both injectable and oral dissolving-tablet formats. It's also LegitScript certified, an independent check on whether a pharmacy or telehealth operator complies with prescribing law — a real trust signal in a market with plenty of unvetted operators, and Willow names its compounding pharmacy partners rather than dodging the question. The constraint is geography: coverage runs to 33 states, so confirm yours is on the list before intake, and there are no live video consultations if that matters to you.

Is compounded semaglutide the same quality and safety as Wegovy?

Same active molecule, different oversight. The FDA reviews Wegovy's potency, sterility, and manufacturing consistency batch to batch; it doesn't review a compounded formulation the same way. That's the practical meaning of "not FDA-approved as a finished product" — no independent agency has verified that your specific vial matches the last one. Some compounded formulations also add ingredients Wegovy doesn't contain, most often B12 or L-carnitine, marketed for energy or metabolism support but not independently evaluated in combination with semaglutide. None of this makes compounded semaglutide inherently unsafe, but it makes the specific pharmacy behind your prescription — not just the telehealth brand on the label — the thing genuinely worth asking about before you start.

Red flags: how to spot a legit vs. sketchy compounding pharmacy

• Markets its product literally as "compounded Wegovy" rather than compounded semaglutide — a provider that misuses a trademark this way is telling you something about how it operates.
• Won't name the 503A pharmacy filling your prescription, or dodges the question when you ask.
• No online consult or clinical review at all — just a checkout page and a shipment.
• Maintenance-dose pricing that isn't published anywhere, even after you ask directly.
• A price meaningfully below everything else on this page with no explanation for how that's possible.

Who compounded semaglutide is — and isn't — a good fit for

• Good fit: women without insurance coverage for weight-loss medication who want supervised semaglutide at the lowest realistic cash-pay cost, and who've confirmed a documented clinical reason with their provider.
• Not ideal: commercially insured women whose plan covers Wegovy — the manufacturer's savings card at around $25 a month will almost always beat any compounded price.
• Always ask: which 503A pharmacy compounds your medication, and what its accreditation and testing practices are.

If weight change in your forties or fifties is what brought you to semaglutide in the first place, the hormonal piece is worth understanding on its own terms — see GLP-1 medications and menopause weight gain for that fuller picture.